CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease

Jeroen E. J. Guikema, Sjoerd Hovenga, Edo Vellenga, Jelle J. Conradie, Wayel H. Abdulahad, Roelof Bekkema, Jan W. Smit, Fenghuang Zhan, John Shaughnessy, Nicolaas A. Bos

Research output: Contribution to journalArticleAcademicpeer-review

62 Citations (Scopus)


Expression of CD27 on malignant plasma cells (PC) (CD138+CD38++) was analysed in a cross-sectional study of bone marrow (BM) samples from multiple myeloma (MM) patients (n = 28), monoclonal gammopathy of undetermined significance (MGUS) patients (n = 6) and BM PC from healthy donors (n = 4). MM PC expressed CD27 with a variable, lower intensity pattern compared with the consistent high expression in MGUS and healthy donors. MM patients in complete clinical remission displayed a higher percentage of CD27+ PC compared with patients at diagnosis, relapse or in partial remission. In MM, loss of CD27 correlated with loss of CD19 (R2 = 0.4, P <0.0001). Human MM cell lines (n = 9) did not express CD27 whereas de novo plasma cell leukaemia (PCL) (n = 3) had a high expression. Re-analysis of a cDNA microarray data set, generated from newly diagnosed MM patients (n = 74), demonstrated that the MM subgroup with the highest prevalence of poor prognostic factors had the lowest CD27 mRNA expression. Fluorescence-activated cell sorting and allele-specific oligonucleotide polymerase chain reaction showed that both CD27+ and CD27- PC subpopulations in MM can belong to the clonal disorder. In conclusion, CD27 is heterogeneously expressed on MM PC and loss of CD27 expression might have prognostic value in MM
Original languageEnglish
Pages (from-to)36-43
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - 2003

Cite this